<DOC>
	<DOC>NCT01218997</DOC>
	<brief_summary>This was a Phase 3 multicenter randomized, open-label, safety study assessing the safety of repeat doses of Medisorb® naltrexone 380 mg (VIVITROL®) administered for up to 1 year to adults with alcohol and/or opioid dependence as defined by Diagnostic and Statistical Manual of Mental Health Disorders (DSM-IV) criteria. Eligible subjects were randomized in a 6:1 ratio to receive 1 of the following regimens: a single intramuscular (IM) injection of VIVITROL administered once every 4 weeks or oral naltrexone 50 mg administered daily.</brief_summary>
	<brief_title>ALK21-006: Long-Term Study of Medisorb® Naltrexone (VIVITROL®)</brief_title>
	<detailed_description>Safety evaluations included physical examinations, electrocardiograms (ECGs), laboratory measures (including plasma concentrations of naltrexone and 6β-naltrexol), assessments of injection sites, and adverse events (AEs). All subjects received psychosocial support at each study visit for the duration of the study, with interim telephone contact 2 weeks after each monthly visit.</detailed_description>
	<mesh_term>Alcoholism</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>Primary Current diagnosis of DSMIV alcohol dependence and/or diagnosis of DSMIV opiate dependence within 3 months prior to screening 18 years or older Desire to seek treatment for alcohol and/or opiate abuse/dependence Agree to use contraception for the study duration if of childbearing potential Written informed consent and willingness to perform study procedures Stable address and phone and at least 1 source of contact information (eg, family member, significant other) Primary Presence of opiates in the urine (as determined by urine drug test) on Day 0 prior to naltrexone treatment Clinically significant medical/psychological condition or abnormality at screening (ie, physical examination, electrocardiogram [ECG], hematology or blood chemistry evaluation, or urinalysis findings) Clinically significant active hepatitis or hepatic failure evidenced by 1 of the following: aspartate transaminase (AST) or alanine transaminase (ALT) higher than 3 times the upper limit of normal (3xULN), hyperbilirubinemia (bilirubin &gt;10% above ULN), creatine phosphokinase (CPK) higher than 10xULN, prolonged prothrombin time(international normalized ratio ≥1.7), ascites, or esophageal variceal disease Manifestation of suicidal ideation, psychotic symptoms (including significant violent behavior), or psychiatric disorders that would compromise ability to complete the study Participation in a formal methadone program currently or within prior 3 years More than 2 prior medically supervised detoxification treatments in prior 3 years Pregnancy or lactation Current prescribed opiate therapy, or receipt of opiates within 7 days prior to study drug dosing, or ongoing medical condition likely to require prescribed opiate therapy during study period Failed naloxone challenge on Day 0 (the challenge could be repeated up to 2 times, with at least 24 hours between attempts) Participation in a clinical trial within 30 days of screening Previous enrollment in a VIVITROL clinical trial Receipt of any drug product administered as a gluteal injection within 180 days prior to Day 0 or anticipated need for gluteal injections during study period Intolerance and/or hypersensitivity to naltrexone, naloxone, or polylactidecopolymers such as polylactidecoglycolide (PLG)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Alcoholism</keyword>
	<keyword>Alcohol dependence</keyword>
</DOC>